Predilection of Clinical Response to Chemotherapy in Head and Neck Cancer -Correlation of Apoptosis related genes and Chemosensitivity-

1.应用SDI试验进行抗癌药敏试验的研究：对55例头颈部肿瘤进行了琥珀酸脱氢酶抑制（SDI）试验。结果，SDI测试的可评价率为80%。来自所涉及的淋巴结的癌细胞显示出低计算抑制率的趋势（即，R.）与原发性肿瘤相比，结果：1.体外实验结果与复发患者经CDDP/5 FU治疗后的临床反应进行比较，CDDP和5 FU的预测准确率分别为56%和63%.一项使用HSRA试验的抗癌药物敏感性试验研究：对40例头颈部癌症进行了具有MTT终点的组织培养药物反应试验（HSP 70）。利用浓度-I.R.曲线和浓度-疗效率曲线，估计CDDP的最佳截止浓度为20 μ g/ml，5 FU为300 μ g/ml，阿霉素为15 μ g/ml。I.R.at CDDP 20 μ g/ml的淋巴结转移率明显低于鳞癌原发灶。将CDDP 20 μ g/ml的体外结果与13例经VDDP/5 FU治疗的患者的临床反应进行比较，发现体外结果与体内结果之间存在显著相关性。化疗反应的预测准确率为77%.免疫组织化学研究：用免疫组化方法检测p53、bcl-2、谷胱甘肽S转移酶（Glucose-S-Transferase，GST）π和金属硫蛋白（Metallothionein，MT）的表达与肿瘤敏感性的关系。p53和MT的阳性染色与较低的CDDP 20 μ g/ml的HSP 70测定显著相关。I.R.at它们对化疗反应的预测准确率分别为75%和50%。结果如下：应用免疫组化法检测肿瘤组织中p53蛋白的表达及抑制作用，可用于头颈部肿瘤化疗疗效的预测。

1. A study of an anticancer drug sensitivity test suing the SDI test : The succinate dehydrogenase inhibition (SDI) test was carried out for 55 head and neck cancers. As a results, the evaluable rate of the SDI test was 80%. Cancer cells from the involved lumph nodes showed a tendency to low calculated inhibition rate (i. R.) as compared with those from primary tumors. The in vitro results were compared with the clinical responses of the recurrent patients who were treated by CDDP/5FU.Predictive accuracies of CDDP and 5FU were 56%and 63%, respectively.2. A study of an anticancer drug sensitivity test using the HSRA test : Histoculture drug response assay (HDRA) with MTT-endpoint was performed for 40 head and neck cancers. using a concentration-I.R.curve and a concentration-efficacy rate curve, the optimal cutoff concentration was estimated as 20mug/ml for CDDP,300mug/ml for 5FU and15mug/ for adriamycin. I.R.at CDDP 20mug/ml from the involved lumph nodes showed a significantly lower value than that of primary tumors of squamous cell carcinoma. The in vitro results at CDDP 20mug/ml were compared with the clinical responses of 13 patients who were treated by VDDP/5FU.Significant correlation between in vitro and in vivo results was observed. The predictive accuracy for response to chamotherapy was 77%.3. Immunohistochamical study : The correlation betwen an anticancer sensitibity test and the status of p53, bcl-2, Glutathione S-Transferase pi and Metallothionein (MT) using immunohistochemical staining was examined. Positive staining of p53 and MT significantly correlated with lower I.R.at CDDP 20mug/ml of HDRA assay. Their predictive accuracy for response to chemotherapy was 75% and 50%, respectively.4. Results : HDRA assay and the status of p53 using immonuhistochamical staining are extremely useful in the prediction of response to chamotheray for head and neck cancer.